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Abstract
Background—A profound thrombocytopenia limits hepatic xenotransplantation in the pig-to-
primate model. Porcine livers also have shown the ability to phagocytose human platelets in the 
absence of immune-mediate injury. Recently, inactivation of the porcine ASGR1 gene has been 
shown to decrease this phenomenon. Inactivating GGTA1 and CMAH genes has reduced the 
antibody-mediated barrier to xenotransplantation; herein we describe the effect that these 
modifications have on xenogeneic consumption of human platelets in the absence of immune-
mediated graft injury.
Methods—WT, ASGR1−/−, GGTA1−/−, and GGTA1−/−CMAH−/− knockout pigs were compared 
for their xenogeneic hepatic consumption of human platelets. An in vitro assay was established to 
measure the association of human platelets with liver sinusoidal endothelial cells (LSECs) by 
immunohistochemistry. Perfusion models were used to measure human platelet uptake in livers 
from WT, ASGR1−/−, GGTA1−/−, and GGTA1−/− CMAH−/− pigs.
Results—GGTA1−/−, CMAH−/− LSECs exhibited reduced levels of human platelet binding in 
vitro, when compared to GGTA1−/− and WT LSECs. In a continuous perfusion model, GGTA1−/− 
CMAH−/− livers consumed fewer human platelets than GGTA1−/− and WT livers. GGTA1−/− 
CMAH−/− livers also consumed fewer human platelets than ASGR1−/− livers in a single pass 
model.
Conclusions—Silencing the porcine carbohydrate genes necessary to avoid antibody-mediated 
rejection in a pig-to-human model also reduces the xenogeneic consumption of human platelets by 
the porcine liver. The combination of these genetic modifications may be an effective strategy to 
limit the thrombocytopenia associated with pig-to-human hepatic xenotransplantation.
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Introduction
The most pressing issue affecting patients awaiting transplant is a growing dearth of 
available allografts. While peak transplanted volumes for all solid organs has plateaued, 
each year the number of patients added to solid-organ wait lists increases.1 As recently 
stated by Salomon et al., from the AST/ASTS workshop on increasing organ donation: “our 
current system of organ donation is not meeting the growing demand”. 2 
Xenotransplantation of genetically modified porcine organs is now positioned to be a 
clinically-viable answer to this growing problem. Advances in genetic engineering have 
rapidly increased the pace at which model organs may be created and tested. 3 Recently, a 
triple knockout model has reduced human antibody binding below the threshold at which 
acute antibody-mediated rejection (AMR) would not be expected. 4 It is from this position 
of immunologic equivalence, that it is now important to examine organ-specific barriers to 
clinical xenotransplantation.
The use of porcine livers for xenotransplantation is limited by a dramatic thrombocytopenia 
when studied in a pig-to-primate model. 5 As described by Burlak et al., 6 porcine sinusoidal 
endothelial cells (LSEC) and Kupffer cells (KC) also remove human platelets from 
circulation in the absence of immunologic injury or sheer-stress activation. Recently, gene 
silencing has been used to limit this thrombocytopenia. As described by Paris et al., 7 
removing the asialoglycoprotein receptor 1 protein from the porcine livers significantly 
reduces the amount of human platelet uptake. Although carbohydrate reductions have 
proved essential to limiting AMR in a pig-to-human model, little attention has been afforded 
to the effect that these modifications may have on hepatic platelet consumption. Silencing of 
the GGTA1 gene, which facilitates cell surface expression of the Galα(1,3)Gal (αGal) 
xenoantigen, and the CMAH gene which allows expression of the N-Glycolylneuraminic 
acid (Neu5Gc) xenoantigen may help avoid early xenogeneic AMR;8 it is therefore 
important to understand the effect that these modifications have on the human 
thromboregulatory system. Herein we describe the effect that silencing the porcine GGTA1 
and CMAH genes has on the consumption of human platelets by a porcine liver.
Methods
Genetically modified pigs
The GGTA1−/−, GGTA1−/−CMAH−/− and ASGR1−/− pigs used in this study have been 
described previously.7,9 Briefly, the same parental background was used across all animals 
to limit variability from external loci. GGTA1 and CMAH gene silencing was accomplished 
by CRISPR/Cas9-directed mutagenesis as described by Li et al. 9 ASGR1 silencing was 
effected by TALEN- directed mutagenesis as described by Paris et al. 710 The Institutional 
Biosafety and Institutional Animal Care and Use Committee at Indiana University School of 
Medicine approved the use of animals in this research.
Platelet Isolation and Staining
One unit of expired human platelets was purchased from a local blood bank. The platelets 
were centrifuged (5 minutes at 5,000×g). The pellet was resuspended in PBS/ACD 50:1 and 
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washed twice. 2×1011 platelets were obtained by count on hemocytometer, of which 25 
percent were labeled with carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, Grand 
Island, NY) as described. 6 Both labeled and unlabeled platelets were added to a total of 1L 
modified Krebs solution 2.0g/L D-glucose, 0.141 g/L MgSO4, 0.16 g/L KH2PO4, 0.35 g/L 
KCl, 6.9 g/L NaCl, 2.10 g/L NaHCO3, 0.37g/L CaCl2, 2.38 g/L HEPES, 1U/mL Heparin 
(Sagent Pharmaceuticals, Schaumburg, IL) pH 7.2-7.4 and then perfused through a Capiox 
BT05 bubble trap (Terumo Medical, Tokyo, Japan) to remove aggregated platelets prior to 
perfusion. Platelets were again counted to account for platelet loss and resuspended at a 
concentration of 1×1010/L in modified Krebs solution. A total of 10L of platelet suspension 
was prepared and was warmed to 37 °C until perfusion.
Perfusion of Livers
Livers were procured from genetically modified animals and flushed at time of procurement 
with HTK solution (Essential Pharmaceuticals, Ewing, NJ, USA). Organs were removed 
from cold preservation within 2 hours and cannulated to achieve definitive control of the 
portal vein, hepatic artery and suprahepatic inferior vena cava and were warmed to a 
controlled temperature range of 35-37 °C by perfusion with warmed Kreb's solution. Livers 
were perfused in an oxygenated and pulsatile circuit as previously described. 7 For the 
single-pass model, sampling occurred simultaneously from the hepatic artery, portal vein 
and suprahepatic inferior vena cava; samples were collected every 30 seconds for 10 
minutes. A sample from the vena cava port was collected at time 0 to calculate a background 
fluorescence which was subtracted from all samples. For the continuous-pass model, a time 
zero sample of platelets was obtained prior to the introduction of platelets, and samples were 
taken from a central reservoir at reported time points and immediately fixed 1:1 in 10 
percent formalin solution prior to counting.
Measuring Xenogeneic Human Platelet Consumption
For the continuous-pass model, each of the time point samples were counted using a 
hemocytometer and total available platelets in the perfusion system were calculated. These 
values were compared to input platelet amounts and percent remaining available platelets 
were calculated. Results were subjected to analysis by ANOVA with repeated measures and 
Tukey's post test to determine significance. Samples obtained from single-pass hepatic 
perfusions were analyzed by measuring the fluorescence (Ex: 485, Em: 525) of 200uL 
perfusate loaded into 96 well micro clear plates (Greiner Bio One, Monroe, NC, USA) on a 
Spectramax M2 plate reader (Molecular Devices Corp., Sunnyvale, CA, USA). Percent 
maximum fluorescence was calculated by comparing individual time points to input 
fluorescence. Percent maximum values were analyzed on Prism software (Graphpad 
Software Inc., La Jolla, CA). Inclusion criteria for statistical analysis required that arterial 
and portal vein fluorescence reached at least 90% of input fluorescence to suggest adequate 
circulation of labeled platelets through the system. Comparison of platelet quantities in the 
perfusate were made once the platelet levels had plateaued indicating that the system had 
reached a steady state. Statistical significance was determined by unpaired t-test of percent 
fluorescence values obtained after inclusion criteria were met.
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Staining and Confocal Microscopy
For histologic analysis by in vitro assay, primary WT, GGTA1−/− , ASGR1−/− and 
CMAH−/−GGTA1−/− LSEC lines were isolated as previously described. 6 Cells were 
cultured for 4 days post isolation at 37 °C and 5% CO2 in clear-bottomed cell culture-treated 
microscopy slide wells (100, 000 cells/well initial concentration). Fresh human platelets 
were isolated from a healthy donor and labeled with carboxyfluorescein succinimidyl ester 
(CFSE) as described above. Four million CFSE-labeled platelets were added to experimental 
wells containing primary endothelial cells and media. Slides were incubated with platelets 
for 60 minutes. Duplicate wells for each group were washed with 150 μL of PBS three times 
then fixed with 50 μL of 4% paraformaldehyde–PBS solution for 20 min. To facilitate 
immunohistochemical visualization, and confirmation of platelet deposition within ex vivo 
platelet-perfused livers, punch biopsies were obtained at the conclusion of perfusions, 
sectioned at 4um and then fixed with 50 μL of 4% paraformaldehyde–PBS solution for 20 
min. Cells and tissues were stained with goat anti-Pig CD31 1:100 (R and D systems, 
Minneapolis, MN) to visualize the endothelial surface, followed by three PBS washes and 
bovine anti-goat IgG DyLight 649 (Jackson Immuno Research Laboratories Inc., West 
Grove, PA). Slides were incubated with secondary antibody for approximately 1 h and then 
washed three times with PBS. DAPI (Invitrogen, Grand Island, NY) was added to all slides 
for 1 min as a nuclear stain followed by two PBS washes. Slides were mounted in ProLong 
Gold (Invitrogen, Grand Island, NY). Confocal microscopy was performed using an 
Olympus FV1000 (Olympus America Inc., Center Valley, PA, USA).
Results
Analysis of In Vitro Human Platelet Uptake
CFSE-labeled human platelets associate less with isolated porcine liver endothelial cells 
from the GGTA1−/−CMAH−/− background compared to GGTA1−/− and WT cells. The ratio 
of human platelets (green) bound by liver endothelial cells (red) was measured by 
colocalization of platelet per CD31+ cell for all 16 fields viewed per cohort. The median 
LSECs per field was 58 and was not significantly different across cohorts (p=0.32). When 
subjected to statistical analysis by ANOVA with Tukey's multiple comparison test, 
GGTA1−/−CMAH−/− LSECs bound significantly fewer human platelets when compared to 
to GGTA1−/− (0.13 vs 0.34 platelets per LSEC p=0.002, n=16) and WT (0.13 vs 0.37 
platelets per LSEC p=0.002 n=16) cells; ASGR1−/− LSECs exhibited significantly less 
platelet binding than GGTA1−/− (0.17 vs 0.34 platelets per LSEC p=0.013, n=16) and WT 
(0.17 vs 0.37 platelets per LSEC p=0.009, n=16) cells. Although GGTA1−/−CMAH−/− 
LSECs appeared to associated fewer human platelets than ASGR1−/− LSECs, the difference 
failed to reach statistical significance (0.13 vs 0.17 platelets per LSEC p= 0.8, n=16). Cells 
from GGTA1−/− and wild type livers exhibited similar levels of platelet retention (0.34 vs 
0.37 platelets per LSEC p=0.99, n=16). The images in Figure 1 are representative of all 
images captured (n= 16 for each cohort).
Analysis of Ex Vivo Perfusion with Human Platelets
Because of the reduced interaction of human platelets with GGTA1−/−CMAH−/− porcine 
liver sinusoidal endothelial cells, perfusion studies were performed to determine if the 
Butler et al. Page 4
Transplantation. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
removal of human platelets from a perfusion circuit was also minimized. In a continuous-
pass model of platelet uptake, GGTA1−/−CMAH−/− livers consumed fewer platelets than 
GGTA1−/− (p<0.0001) and WT (p<0.0001) livers at every time point (Figure 2). We have 
previously demonstrated that eliminating the asialoglycoprotein receptor from pig livers 
reduced human platelet consumption when compared to WT; 7 when compared within this 
analysis, these findings were confirmed (p<0.0001). Although a trend towards lower platelet 
uptake was noticed when comparing GGTA1−/−CMAH−/− to ASGR1−/− livers, the 
difference failed to reach statistical significance at two of the time points within this model 
(p<0.161). Representative immunochemical histology obtained post continuous pass 
perfusion is shown in Figure 2B and confirms that the loss of platelets through the system is 
a function of hepatic deposition.
To better characterize the difference between GGTA1−/−CMAH−/− livers and ASGR1−/− 
livers, we sought to increase the sensitivity of our perfusion model. Though continuous pass 
circuits are sufficient for demonstrating large differences in platelet uptake, it was 
insufficient to reliably measure more subtle differences. Consequently, we developed a 
“single pass” perfusion circuit to examine the loss of platelets following transit through the 
organ a single time (SDC Figure 1). Serial samples were collected until the input (artery and 
portal vein,) and the output (vena cava) reached a plateau, indicating steady state had been 
reached (Figure 3). After plateau phase was achieved, data from time points 390, 420 and 
450 seconds were averaged (Figure 3D); suprahepatic inferior vena cava fluorescence 
reached 95.4% (SEM=0.590) of initial sample fluorescence for GGTA1−/− CMAH−/− livers 
compared to 83.9% (SEM=0.513) in ASGR1−/− livers during steady-state. (P= 0.001, 
GGTA1−/− CMAH−/− n=3, ASGR1−/− n= 4)
Discussion
Xenotransplantation of genetically modified porcine organs offers an imminent answer to 
the growing shortage of available allografts for transplantation. With the recent success of 
new knockout models, the antibody barrier to clinical application has effectively been 
crossed. 4 Prior to human trials, it is important to understand the physiologic compatibility 
of these organs with the human thromboregulatory system. Pig-to-primate and pig-to-human 
models of hepatic xenotransplantation are challenged by early thrombocytopenia. Although 
activated human platelets will interact with all porcine endothelial cells, the porcine liver is 
uniquely capable of removing unactivated platelets from circulation. 6,11 Though the 
mechanism remains poorly understood, it appears that porcine asialoglycopritein receptor 
and Von Willebrand factor may contribute to this interaction. 12-15 Recent efforts to reduce 
xenogeneic thrombocytopenia in a pig-to-primate model have also exposed the importance 
of limiting immune-mediated graft injury. 16,17 Judicious immunosuppression has prevented 
thrombocytopenia following pig-to-primate xenotransplantation of the porcine heart and 
kidney. 18,19 Given this information, it is possible that a combination of immunosuppression 
and the reduced antigenicity of newer knockout porcine donors alone may facilitate success 
for renal or cardiac xenografts. Owed to the inherently phagocytic tendency of the liver, 
further modifications will be necessary to avoid thrombocytopenia with hepatic xenografts.
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The porcine ASGR1 gene produces the asialoglycoprotein receptor, which is known to bind 
and clear human platelets. Paris et al. previously demonstrated that ASGR1−/− livers 
consume fewer human platelets than WT livers, making them a more appropriate 
comparison for the present study. 7 GGTA1 and CMAH genes produce carbohydrates on the 
porcine cell surface; humans and primates have inactivated these genes over the course of 
evolution and therefore carry pre-formed antibodies against the products. Silencing these 
carbohydrate genes results in a favorable crossmatch against human sera, and therefore will 
be necessary for clinical application of pig-to-human xenotransplantation. 8 Surprisingly, 
these same modifications that have reduced the xenoantigen barrier also reduce the 
consumption of human platelets by the porcine liver, even in the absence of immune-
mediated injury. Elimination of the CMAH gene appears to provide the majority of 
protection from platelet consumption.
Though the relationship between carbohydrate profiles and hepatic platelet uptake is still 
being defined, the ability of carbohydrates to affect hepatic recognition and transport has 
been recognized for over 30 years. 20 More recently, hepatic lectins and surface 
carbohydrates have been implicated in the process of hepatic platelet consumption. 21-23 
Although the specific role of Neu5Gc (CMAH gene product) remains unknown, its induced 
expression on human atherosclerotic plaques 24 and cancer cells 25 in vivo suggests a link 
between altered N-glycan structure and human platelet adhesion. It is plausible that the 
induced expression of Neu5Gc in human solid-organ malignancies is partially responsible 
for the tumor-induced prothrombotic state, and that Neu5Gc-mediated aggregation is 
responsible for the human platelet's supportive role in tumor metastasis. 26
Humanizing the porcine carbohydrate profile significantly reduces xenogeneic consumption 
of human platelets by the porcine liver. Simultaneous silencing of the GGTA1 and CMAH 
genes outperformed both GGTA1−/− and ASGR1−/− livers with respect to reduction in 
human platelet uptake. It is likely that a combination of carbohydrate and receptor protein 
knockout strategies will limit the xenogeneic thrombocytopenia associated with pig-to-
human hepatic transplantation and facilitate clinical application.
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Figure 1. Human platelet accumulation by GGTA1−/−CMAH−/−, GGTA1−/−, ASGR1−/−, and 
WT liver sinusoidal endothelial cells in vitro
Primary WT, GGTA1−/−, ASGR1−/− and CMAH−/−GGTA1−/− LSEC lines were isolated 
and cultured for 4 days. Human platelets were isolated from a healthy donor and labeled 
with carboxyfluorescein succinimidyl ester (CFSE). Labeled Platelets (Green) were added to 
experimental wells containing primary endothelial cells. Cells were stained with anti-Pig 
CD31 (Red) to visualize the endothelial surface; and DAPI (Blue) was added to all slides as 
a nuclear stain. Confocal microscopy was performed using an Olympus FV1000. The 
relationships between human platelets and GGTA1−/−CMAH−/− or GGTA1−/− livers seen in 
the ex vivo perfusion model was upheld by in vitro analysis. Based on colocalization 
analysis, CFSE-labeled human platelets associated less with porcine liver endothelial cells 
from the GGTA1−/−CMAH−/− background compared to WT (p=0.002) and GGTA1−/− 
(p=0.002) cells; ASGR1−/− LSECs exhibited significantly less platelet binding than 
GGTA1−/− (p=0.013) and WT (p=0.009) cells. Although GGTA1−/− CMAH−/− LSECs 
appeared to associate fewer human platelets than ASGR1−/− LSECs, the difference failed to 
reach statistical significance (p= 0.8). Figure is representative of all images captured (n= 16 
for each cohort).
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Figure 2. A Continuous-pass model for the xenogenic consumption of human platelets by 
modified porcine livers
(A) In a continuous-pass model of platelet uptake, both GGTA1−/− CMAH−/− and 
ASGR1−/− livers consumed fewer platelets than GGTA1−/− or WT livers (p<0.0001 for all 
comparisons). Platelet disappearance from the system was less at each measured time point 
after time zero. Although a trend towards lower platelet uptake was noticed when comparing 
GGTA1−/−CMAH−/− to ASGR1−/− livers, the difference failed to reach statistical 
significance at two of the time points within this model (p<0.161). (GGTA1−/− n=2, 
GGTA1−/− CMAH−/− n=3, WT n=3 and ASGR1−/− n=3). The ASGR1−/− data was 
published previously and used here with permission. 7 (B) Representative immunochemical 
histology obtained from post continuous pass perfusion hepatic tissue sectioning is shown 
and confirms that the loss of platelets through the system is a function of hepatic deposition. 
Labeled Platelets (Green) were added to experimental wells containing primary endothelial 
cells. Cells were stained with anti-Pig CD31 (Red) to visualize the endothelial surface. 
Confocal microscopy was performed using an Olympus FV1000. Images are representative 
of all samples viewed (n= 6 for each perfusion).
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Figure 3. A single-pass model of human platelet uptake for GGTA1−/− CMAH−/− and ASGR1−/− 
livers
To further characterize a trends noted within a continuous pass model, livers of a GGTA1−/− 
CMAH−/− background were compared to ASGR1−/− livers in a more sensitive single pass 
model. Livers of a GGTA1−/− CMAH−/− background consumed significantly fewer platelets 
than ASGR1−/− livers in a single-pass model of human platelet uptake. After the addition of 
CFSE-labeled human platelets into the circuit diagramed in SDC Figure 1B, samples were 
obtained simultaneously from the hepatic artery (A), portal vein (B), and suprahepatic 
inferior vena cava (C), over time and measured for fluorescence. Each sample was measured 
against the pre-perfusion fluorescence measurement to achieve a percent input fluorescence 
value. (D) After plateau phase was achieved, data from time points 390, 420 and 450 
seconds were averaged; suprahepatic inferior vena cava fluorescence reached 95.4% 
(SEM=0.590) of initial sample fluorescence for GGTA1−/− CMAH−/− livers compared to 
83.9% (SEM=0.513) in ASGR1−/− livers during steady-state. (P= 0.001, GGTA1−/− 
CMAH−/− n=3, ASGR1−/− n= 4) Representative immunochemical histology obtained post 
single pass perfusion is shown at figure right and confirms that the loss of platelets through 
the system is a function of hepatic deposition.
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